TriLink BioTechnologies® and Quantoom Biosciences Sign License and Supply Agreement for CleanCap® mRNA Capping Technology

Quantoom’s customers can now access TriLink’s CleanCap mRNA capping technology; Agreement supports future expansion of essential therapeutics & vaccines in developing countries & regions

SAN DIEGO (June 3, 2025)

TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Under the agreement, Quantoom will have access to TriLink’s CleanCap® mRNA capping technology for integration in its Ntensify® (sa)mRNA production platform to help accelerate the RNA production process and make life-saving therapeutics and vaccines more accessible to patients worldwide.

TriLink’s CleanCap technology produces optimal 5′ cap structures with over 95% efficiency, creating a co-transcriptional capping solution that dramatically improves mRNA yield and process time when compared to legacy capping methods. Under this agreement, TriLink will supply its patented CleanCap technology for use in Quantoom’s (sa)mRNA production platform, allowing customers to benefit from the industry’s leading capping technology to develop their unique (sa)mRNA drugs using the Ntensify platform through clinical development phases.

“Strengthening global health against infectious diseases requires strong industry partnerships,” said Becky Buzzeo, Chief Commercial Officer at Maravai. “We’re excited for the Quantoom production platform to incorporate TriLink’s CleanCap reagents, a proven mRNA capping technology to deliver essential therapeutics and vaccines to nations with limited resources.”

Since its debut in 2017, TriLink’s CleanCap capping technology has transformed the mRNA capping industry and is used in the majority of all approved COVID-19 mRNA and saRNA vaccines.

“We are committed to making the RNA technology more accessible and scalable, and this partnership with TriLink is a key step toward that goal,” said José Castillo, CEO of Quantoom Biosciences. “By integrating CleanCap analogs into our platform, we can further empower researchers and manufacturers to develop life-saving vaccines and therapeutics for communities in need.”

About TriLink BioTechnologies

TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans. For more information about TriLink, visit trilinkbiotech.com

Contact Information: